Volume 29, issue 5, May 2022
134 articles in this issue
1. ASO Perspectives: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer: Never Stop Questioning
2. ASO Editorial: Could Physician–Patient Communication Make a Difference in Cancer-Related Fatigue in Esophageal Cancer?
3. Improving Esophagectomy Outcomes in France: Petit a Petit
4. Prognostic Biomarkers in Melanoma: The Legacy of a Surgeon Scientist Who Followed the Data
5. The Importance of Studying Our Surveillance Strategies
6. Circulating Tumor Cells and Breast Cancer: The Long and Winding Road Behind and Before Us
7. Lipid Metabolism in Biliary Tract Cancer: A New Therapeutic Target?
8. Use of Large Retrospective Databases to Guide Tumor Staging Criteria
9. A Colon Resection and Pump Implantation in the Same Surgical Procedure: Is it Safe?
10. Progress and Persistent Challenges in Improving Care for Low-Income Women with Breast Cancer
11. Oncological Risk of Colonic Stents Used as Bridge to Surgery for Left-Side Malignant Colonic Obstructions
12. The Impact of Ulcerative Colitis on Colorectal Cancer Prognosis: The Jury is Still Out
13. Diversity Among Surgical Faculty, Residents, and Oncology Fellows from 2011/2012 to 2019/2020
14. ASO Research Letter: Trends in Location of Death for Individuals with Pancreatic Cancer in the United States
15. Evaluating the Effects of a Tissue Selective Estrogen Complex (TSEC) in Women with Newly Diagnosed Ductal Carcinoma In Situ
16. Adjuvant Nivolumab or Ipilimumab + Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab
17. Global Forum of Cancer Surgeons: Cancer Surgery During the COVID-19 Pandemic: Impact and Lessons Learned
18. The Trajectory of Cancer-Related Fatigue and Its Associating Factors in Patients with Esophageal Cancer Receiving Treatments: A Prospective Longitudinal Study
19. Effect of Phased Implementation of Totally Minimally Invasive Ivor Lewis Esophagectomy for Esophageal Cancer after Previous Adoption of the Hybrid Minimally Invasive Technique: Results from a French Nationwide Population-Based Cohort Study
20. ASO Author Reflections: The Hybrid Technique as a Guide in the Transition from Open to Totally Minimally Invasive Esophagectomy—Lessons from a Nationwide Population-Based Study
21. ASO Video Abstract: Effect of Phased Implementation of Totally Minimally Invasive Ivor Lewis Esophagectomy for Esophageal Cancer after Previous Adoption of the Hybrid Minimally Invasive Technique: Results from a French Nationwide Population-Based Cohort Study
22. Life Expectancy in Survivors of Esophageal Cancer Compared with the Background Population
23. Robotic Techniques in Esophagogastric Cancer Surgery: An Assessment of Short- and Long-Term Clinical Outcomes
24. ASO Author Reflections: Modern-Day Implementation of Robotic Esophagogastric Cancer Surgery
25. ASO Visual Abstract: Robotic Techniques in Esophagogastric Cancer Surgery: An Assessment of Short- and Long-Term Clinical Outcomes
26. Comparison of Long-Term Outcomes Between Minimally Invasive Pulmonary Resection With and Without Video-Assisted Mediastinoscopic Lymphadenectomy for Left-Sided Lung Cancer
27. ASO Author Reflections: Could VAMLA be a Therapeutic Strategy in Selected Patients with Left-sided NSCLC?
28. Cancer-Related Fatigue After Esophageal Cancer Surgery: Impact of Postoperative Complications
29. ASO Visual Abstract: Cancer-Related Fatigue after Esophageal Cancer Surgery—Impact of Postoperative Complications
30. Correction to: Lymphatic Node Metastasis Risk Scoring System: A Novel Instrument for Predicting Lymph Node Metastasis After Thymic Epithelial Tumor Resection
31. Is There a Relationship Between TILs and Regression in Melanoma?
32. ASO Author Reflections: Is There a Relationship Between TIL and Regression in Melanoma?
33. ASO Visual Abstract: Is There a Relationship Between Tumor-Infiltrating Lymphocytes (TILs) and Regression in Melanoma?
34. The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma
35. Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer
36. ASO Author Reflections: Advancing Circulating Tumor Cells as Liquid Biopsies to Efficiently Target Metastatic Breast Cancer
37. ASO Visual Abstract: Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer
38. ACAT-1-Regulated Cholesteryl Ester Accumulation Modulates Gemcitabine Resistance in Biliary Tract Cancer
39. ASO Author Reflections: ACAT-1-Regulated Cholesteryl Ester Accumulation Modulates Gemcitabine Resistance in Biliary Tract Cancer
40. ASO Visual Abstract: ACAT-1-Regulated Cholesteryl Ester Accumulation Modulates Gemcitabine Resistance in Biliary Tract Cancer
41. Tumor-Infiltrating Lymphocytes (TILs) as a Biomarker of Abscopal Effect of Cryoablation in Breast Cancer: A Pilot Study
42. ASO Author Reflections: How can we Measure an Abscopal Effect Seen with Cryoablation?
43. ASO Visual Abstract: Tumor-Infiltrating Lymphocytes (TILs) as a Biomarker of Abscopal Effect of Cryoablation in Breast Cancer—A Pilot Study
44. The Novel Tumor Microenvironment-Related Prognostic Gene AIF1 May Influence Immune Infiltrates and is Correlated with TIGIT in Esophageal Cancer
45. ASO Author Reflection: The TME-Related Gene AIF1 Signature Predicts Esophageal Carcinoma Prognosis
46. ASO Visual Abstract: The Novel Tumor Microenvironment-related Prognostic Gene AIF1 May Influence Immune Infiltrates and is Correlated with TIGIT in Esophageal Cancer
47. TRPV2 Promotes Cell Migration and Invasion in Gastric Cancer via the Transforming Growth Factor-β Signaling Pathway
48. ASO Author Reflections: TRPV2 and Gastric Cancer
49. ASO Visual Abstract: TRPV2 Promotes Cell Migration and Invasion in Gastric Cancer via the TGF-β-Signaling Pathway
50. Preoperative Microvascular Invasion Prediction to Assist in Surgical Plan for Single Hepatocellular Carcinoma: Better Together with Radiomics
51. ASO Author Reflections: Preoperative Microvascular Invasion Prediction to Assist in Surgical Plan for Single Hepatocellular Carcinoma—A Better Algorithm of Necessity
52. ASO Visual Abstract: Preoperative Microvascular Invasion Prediction to Assist in the Surgical Plan for Single Hepatocellular Carcinoma: Better Together With Radiomics
53. ASO Author Reflections: Impact of Tumor Necrosis on Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma
54. Pure Laparoscopic Right Upper Transversal Hepatectomy
55. ASO Author Reflections: Pure Laparoscopic Right Upper Transversal Hepatectomy
56. Laparoscopic Segmentectomy IV Using Hepatic Round Ligament Approach Combined with Fluorescent Negative Staining Method
57. ASO Author Reflections: How to Choose the Optimal Surgical Strategy to Finish Laparoscopic Anatomical Hepatectomy for a Solitary HCC in the Left Lobe?
58. Laparoscopic Left Hepatectomy for Hepatocellular Carcinoma Recurrence Following Liver Transplantation
59. Surgical Management of Axilla of Triple-Negative Breast Cancer in the Z1071 Era: A Propensity Score-Matched Analysis of the National Cancer Database
60. ASO Visual Abstract: Surgical Management of the Axilla of Triple-Negative Breast Cancer in the Z1071 Era—A Propensity-Score Matched Analysis of the National Cancer Database
61. Short-Term Outcomes Following Breast Cancer Surgery With and Without Neoadjuvant Chemotherapy: A Nationwide Administrative Database Study in Japan
62. ASO Author Reflections: Neoadjuvant Chemotherapy Does Not Affect Short-Term Outcomes After Breast Cancer Surgery
63. ASO Visual Abstract: Short-Term Outcomes Following Breast Cancer Surgery With and Without Neoadjuvant Chemotherapy: A Nationwide Administrative Database Study in Japan
64. A Prospective Study Evaluating the Accuracy of Indocyanine Green (ICG) Fluorescence Compared with Radioisotope for Sentinel Lymph Node (SLN) Detection in Early Breast Cancer
65. ASO Visual Abstract: A Prospective Study Evaluating the Accuracy of Indocyanine Green (ICG) Fluorescence Compared with Radioisotope for Sentinel Lymph Node (Sln) Detection in Early Breast Cancer
66. Surgeon and Patient Reports of Fertility Preservation Referral and Uptake in a Prospective, Pan-Canadian Study of Young Women with Breast Cancer
67. ASO Author Reflections: Referring Young Breast Cancer Patients for Fertility Preservation: Significant Progress but Still Room for Improvement
68. ASO Visual Abstract: Surgeon and Patient Reports of Fertility Preservation Referral and Uptake in a Prospective Pan-Canadian Study of Young Women with Breast Cancer
69. Outcomes of Sentinel Node Biopsy for Women with Breast Cancer After Neoadjuvant Therapy: Systematic Review and Meta-Analysis of Real-World Data
70. ASO Visual Abstract: Outcomes of Sentinel Node Biopsy in Women with Breast Cancer Following Neoadjuvant Therapy—Systematic Review and Meta-Analysis of Real-World Data
71. Sociodemographic and Clinical Predictors of Neoadjuvant Chemotherapy in cT1-T2/N0 HER2-Amplified Breast Cancer
72. ASO Visual Abstract: Sociodemographic and Clinical Predictors of Neoadjuvant Chemotherapy in cT1-T2/N0 HER2-Amplified Breast Cancer
73. Correction to: Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer
74. Standardized Procedure of Transperineal Minimally Invasive Abdominoperineal Resection for Low Rectal Cancer
75. ASO Author Reflections: What is the Most Reasonable Approach to Abdominoperineal Resection for Low Rectal Cancer?
76. Laparoscopic Pelvic Exenteration with Bladder Sparing for Men with Locally Advanced Rectal Cancer (with Video)
77. ASO Visual Abstract: Laparoscopic Pelvic Exenteration with Bladder Sparing for Men with Locally Advanced Rectal Cancer
78. Laparoscopic Anterior Resection with Anastomosis of Mid-Transverse to Distal Rectum with Deloyers Procedure Under Indocyanine Green fluorescence Guidance: A Video Case Report
79. Shifting Paradigms in the Pathophysiology and Treatment of Carcinoid Crisis
80. Robotic Adrenalectomy Using the da Vinci SP Robotic System: Technical Feasibility Comparison with Single-Port Access Using the da Vinci Multi-arm Robotic System
81. Which Is the Best Endoscopic Procedure for Thyroid Gland?
82. Response to the Letter: Which is the Best Endoscopic Procedure for Thyroid Gland?
83. Impact of Surgical Margins on Overall Survival after Gastrectomy for Gastric Cancer: A Validation of Japanese Gastric Cancer Association Guidelines on a Western Series
84. ASO Author Reflections: Less is more: Organ-Sparing Approach for the Surgical Treatment of Gastric Adenocarcinoma
85. ASO Visual Abstract: Impact of Surgical Margins on Overall Survival After Gastrectomy for Gastric Cancer: A Validation of Japanese Gastric Cancer Association Guidelines on a Western Series
86. Nativity Status is an Important Social Determinant of Health for Hispanic Patients with Gastric Cancer in Texas
87. Racial Disparities in Surgery for Malignant Bowel Obstruction
88. ASO Visual Abstract: Racial Disparities in Surgery for Malignant Bowel Obstruction
89. Disparities in Utilization and Outcomes of Minimally Invasive Techniques for Gastric Cancer Surgery in the United States
90. ASO Visual Abstract: Disparities in Utilization and Outcomes of Minimally Invasive Techniques for Gastric Cancer Surgery in the United States
91. Physiotherapy Regimens in Esophagectomy and Gastrectomy: a Systematic Review and Meta-Analysis
92. ASO Author Reflections: The Role of Physiotherapy Regimens in Esophagectomy and Gastrectomy for Cancer
93. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined with Surgery: A 12-Year Meta-Analysis of this Promising Treatment Strategy for Advanced Gastric Cancer at Different Stages
94. ASO Author Reflections: Clinical Research and Application Prospect of HIPEC Combined with Surgery in Advanced Gastric Cancer
95. The Effect of Interaction Between Lymph Node Ratio and pN Stage
96. Comment on “Surgical Outcomes and Comparative Analysis of Transduodenal Ampullectomy and Pancreaticoduodenectomy: A Single-Center Study”
97. Correction to: A Population-Based Analysis of Long-Term Outcomes Among Older Adults Requiring Unexpected Intensive Care Unit Admission After Cancer Surgery
98. Correction to: Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis
99. Socioeconomic Disparities in Pancreas Cancer Resection and Survival in the Veterans Health Administration
100. ASO Author Reflections: Socioeconomic Disparities in Pancreas Cancer Resection and Survival in the Veterans Health Administration
101. ASO Visual Abstract: Socioeconomic Disparities in Pancreas Cancer Resection and Survival in the Veterans Health Administration
102. Surgery for Intraductal Papillary Mucinous Neoplasms of the Pancreas: Preoperative Factors Tipping the Scale of Decision-Making
103. ASO Author Reflections: Surgery for Intraductal Papillary Mucinous Neoplasm: Predicting Risk for Better Patient Selection
104. ASO Visual Abstract: Surgery for IPMN of the Pancreas—Preoperative Factors Tipping the Scale of Decision-Making
105. Prognostic Effect of Aberrant Right Hepatic Artery with Pancreaticoduodenectomy: Focus on Hepatic Recurrence
106. ASO Author Reflections: Aberrant Right Hepatic Artery Anatomy, an Independent Prognostic Factor for Hepatic Recurrence of Pancreatic Cancer
107. ASO Visual Abstract: Prognostic Effect of Aberrant Right Hepatic Artery with Pancreaticoduodenectomy—Focus on Hepatic Recurrence
108. Disparities in Access to Oncologic Care in Pancreatic Cancer: A Systematic Review
109. ASO Visual Abstract: Disparities in Access to Oncologic Care in Pancreatic Cancer—A Systematic Review
110. Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis: A Report from the Children’s Oncology Group Study AREN0534
111. ASO Video Abstract: Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis—A Report from the Children’s Oncology Group Study AREN0534
112. Delayed Gastric Emptying After Multivisceral Resection for Retroperitoneal Sarcoma
113. ASO Author Reflection: Delayed Gastric Emptying as a Sentinel Event of Severe Complications in Retroperitoneal Sarcoma Surgery
114. ASO Video Abstract: Delayed Gastric Emptying After Multivisceral Resection for Retroperitoneal Sarcoma
115. Refining the Approach to Patients with Primary Soft Tissue Sarcoma of the Extremities and Trunk Wall: Outcome Improvement Over Time at a Single Institution
116. ASO Author Reflections: Outcome Improvement Over Time in Extremity and Trunk Wall Soft Tissue Sarcomas: To Whom the Merit?
117. ASO Visual Abstract: Refining the Approach to Patients with Primary Soft Tissue Sarcoma of the Extremities and Trunk Wall—Outcome Improvement over Time at a Single Institution
118. Extremity Soft Tissue Sarcoma: A Multi-Institutional Validation of Prognostic Nomograms
119. ASO Author Reflections: Utility of Prognostic Nomograms for Extremity Soft Tissue Sarcoma
120. ASO Visual Abstract: Extremity Soft Tissue Sarcoma—A Multi-institutional Validation of Prognostic Nomograms
121. Perineural Invasion is a Powerful Prognostic Factor for Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy
122. ASO Author Reflections: Prognostic Significance of Perineural Invasion in Upper Tract Urothelial Carcinoma
123. ASO Visual Abstract: Perineural Invasion is a Powerful Prognostic Factor for Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy
124. Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients
125. ASO Author Reflections: Cisplatin- and Adrenaline-Based Intraperitoneal Chemotherapy Protocol for Ovarian Peritoneal Carcinosis: New Perspectives?
126. Cytoreductive Surgery with HIPEC is a Safe and Effective Palliative Option in Chemorefractory Symptomatic Peritoneal Metastasis
127. ASO Author Reflections: Palliative Management of Peritoneal Metastasis Exploring the Risks and Benefits of CRS/HIPEC, a Distinctly Different Context Than Early CRS/HIPEC Intervention With ‘Curative Intent’
128. ASO Visual Abstract: Cytoreductive Surgery with HIPEC is a Safe and Effective Palliative Option in Chemo-Refractory Symptomatic Peritoneal Metastasis
129. Letter to the Editor: Comment on ‘‘Cytoreductive Surgery with or without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial’’
130. The Debatable Role of HIPEC in Ovarian Cancer
131. Enigma of Hyperthermic Intraperitoneal Chemotherapy with Interval Cytoreduction Surgery: Need to Push More Boundaries!
132. Combining HIPEC to Interval Surgery in Ovarian Cancer? One Step Forward with a Second Randomized Study: Comment on “Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer—A Phase 3 Clinical Trial”
133. A Comment on a Recent Failed HIPEC Trial
134. Post-Publication Discussion Regarding Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer